排序方式: 共有3条查询结果,搜索用时 0 毫秒
1
1.
为探讨利用TnI-fast 基因进行卵巢癌基因治疗的有效性及其机制, 将TnI-fast基因 cDNA转染人卵巢癌细胞系SKOV3. 采用MTT法和流式细胞技术分别检测TnI-fast基因转染、空载体转染和未转染的SKOV3细胞体外生长状态. 收集3种细胞培养上清液, 检测3种培养上清液对人脐静脉内皮细胞增殖抑制效应. 3种细胞分别接种到裸鼠, 观察肿瘤生长、细胞凋亡、肿瘤血管生成和TnI-fast基因局部表达. 体外试验发现, 与空载体转染和未转染的SKOV3细胞比较, TnI-fast基因表达对肿瘤细胞自身的生长无抑制作用, 但可抑制人脐静脉内皮细胞增殖. 动物实验中, TnI-fast基因表达可显著抑制肿瘤生长, 生长抑制率达73%. 其肿瘤细胞增殖率与对照组相当, 但微血管密度显著降低, 细胞凋亡显著增加. 提示, 肿瘤自身血管生成抑制可显著延缓卵巢癌生长. 利用血管生成特异性抑制基因TnI-fast进行抗肿瘤血管生成基因治疗可作为肿瘤治疗的新策略之一. 相似文献
2.
Expression of the human fast-twitch skeletal muscle troponin I cDNA in a human ovarian carcinoma suppresses tumor growth 下载免费PDF全文
Xiong GuangWu Yang Li Wei YuQuan Wang ShiLang Tian Ling Lei Song Kan Bing Mao YongQiu 《中国科学C辑(英文版)》2007,50(1):93-100
To explore the efficiency and mechanism of ovarian carcinoma gene therapy with the human fast-twitch skeletal muscle troponin
I gene (Tnl-fast), Tnl-fast cDNA was transferred into human ovarian adenocarcinoma cell-line SK-OV-3. In vitro, the cell growth and cell cycle of Tnl-fast-, vector-, and mock-transfected cells were determined by MTT and flow cytometry
assay, respectively. The conditioned media of Tnl-fast-, vector-, and mock-transfected SK-OV-3 cells were collected, and the
cell proliferation inhibiting rates of human umbilical cord venous endothelial cells (HUVECs) by the three conditioned media
were assayed. All the three cell lines were implanted into node mice, and the tumor growth, cell apoptosis, angiogenesis,
and expression of Tnl-fast were observed or analyzed, respectively. In vitro, expression of Tnl-fast protein had no inhibiting effect on the growth of the dominant and stable transfectant cells, but
endothelium, when compared with vector-transfected cells and nontransfected parental SK-OV-3 cells. Implantation of stable
clone expressing Tnl-fast in the female BALB/c nude mice inhibits primary tumor growth by an average of 73%. The nude mice
grafts expressing Tnl-fast exhibit a significant decrease of microvascular density, a higher rate of tumor cells apoptosis
and a comparable proliferation rate as control. Our study, to our knowledge, shows the slowed down growth of the primary ovarian
carcinoma, suggested that grafts were self-inhibitory by halting angiogenesis. Our data might also provide a novel useful
strategy for cancer therapy by antiangiogenic gene therapy with a specific angiogenesis inhibitor Tnl-fast. 相似文献
3.
Xiong GuangWu Yang Li Wei YuQuan Wang ShiLang Tian Ling Lei Song Kan Bing Mao YongQiu 《中国科学:生命科学英文版》2007,50(1):93-100
To explore the efficiency and mechanism of ovarian carcinoma gene therapy with the human fast-twitch skeletal muscle troponin I gene (TnI-fast), TnI-fast cDNA was transferred into human ovarian adeno-carcinoma cell-line SK-OV-3. In vitro, the cell growth and cell cycle of TnI-fast-, vector-, and mock-transfected cells were determined by MTT and flow cytometry assay, respectively. The condi-tioned media of TnI-fast-, vector-, and mock-transfected SK-OV-3 cells were collected, and the cell pro-liferation inhibiting rates of human umbilical cord venous endothelial cells (HUVECs) by the three conditioned media were assayed. All the three cell lines were implanted into node mice, and the tumor growth, cell apoptosis, angiogenesis, and expression of TnI-fast were observed or analyzed, respec-tively. In vitro, expression of TnI-fast protein had no inhibiting effect on the growth of the dominant and stable transfectant cells, but endothelium, when compared with vector-transfected cells and nontrans-fected parental SK-OV-3 cells. Implantation of stable clone expressing TnI-fast in the female BALB/c nude mice inhibits primary tumor growth by an average of 73%. The nude mice grafts expressing TnI-fast exhibit a significant decrease of microvascular density, a higher rate of tumor cells apoptosis and a comparable proliferation rate as control. Our study, to our knowledge, shows the slowed down growth of the primary ovarian carcinoma, suggested that grafts were self-inhibitory by halting angio-genesis. Our data might also provide a novel useful strategy for cancer therapy by antiangiogenic gene therapy with a specific angiogenesis inhibitor TnI-fast. 相似文献
1